Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Paragon 28, Inc. for alleged securities fraud. The firm encourages investors who suffered losses exceeding $75,000 in Paragon 28 between May 5, 2023, and August 8, 2024, to contact them directly to discuss their options. The investigation centers around allegations that Paragon 28 made false and misleading statements about its financial performance and internal controls.
Faruqi & Faruqi, LLP, a leading securities law firm, is investigating potential claims against CrowdStrike Holdings, Inc. after the company experienced significant outages affecting millions of users. Investors who lost over $100,000 due to CrowdStrike’s stock decline between November 29, 2023, and July 29, 2024, are encouraged to contact the firm to discuss their legal options.
Faruqi & Faruqi, LLP, a prominent securities law firm, is investigating potential legal claims against Nano Nuclear Energy Inc. (NNE) on behalf of investors who suffered losses exceeding $50,000 between May 8, 2024, and July 18, 2024. The investigation centers around allegations that NNE made misleading statements about its progress and capabilities, potentially impacting investor confidence and leading to stock price decline.
Faruqi & Faruqi, LLP, a securities law firm, is investigating potential claims against Starbucks Corporation for misleading investors about its financial performance. The firm is seeking a lead plaintiff for a class action lawsuit, and investors who suffered losses exceeding $100,000 between November 2, 2023, and April 30, 2024, are encouraged to contact the firm to discuss their options.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lifecore Biomedical, Inc. (LFCR) following a series of disclosures regarding accounting irregularities and a potential delisting from Nasdaq. The firm encourages investors who suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 to contact them for a free consultation.
The Gross Law Firm is urging shareholders of NANO Nuclear Energy Inc. (NNE) who purchased shares between May 8, 2024 and July 18, 2024, to contact them about a potential class action lawsuit. The complaint alleges that NNE made false statements about its progress towards regulatory approval and its commercialization timelines.
Faruqi & Faruqi, LLP is investigating potential claims against Stellantis N.V. following a significant drop in earnings and allegations of misleading statements concerning inventory levels, pricing, and market share. Investors who suffered losses exceeding $100,000 between February 15, 2024 and July 24, 2024 are encouraged to contact the firm to discuss their legal options.
Faruqi & Faruqi, LLP, a leading securities law firm, is investigating potential claims against SeaStar Medical Holding Corporation (SeaStar). The firm alleges that SeaStar made false and misleading statements about its compliance controls, financial controls, and regulatory prospects. The investigation follows SeaStar’s announcement of a restatement of its financial statements for fiscal year 2022 and subsequent interim periods. Investors who suffered losses exceeding $50,000 are encouraged to contact Faruqi & Faruqi to discuss their legal options.
Investors who purchased American Airlines securities between January 25, 2024, and May 28, 2024, have until September 16, 2024, to file lead plaintiff applications in a securities class action lawsuit against the company. The lawsuit alleges that American Airlines failed to disclose crucial information regarding its financial performance, resulting in a significant stock price drop.
Faruqi & Faruqi, LLP, a leading securities law firm, is investigating potential claims against SeaStar Medical Holding Corporation (SeaStar) and reminds investors of the September 6, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the company. The lawsuit alleges that SeaStar made false and misleading statements about its financial controls and regulatory prospects, leading to a restatement of its financial statements and a subsequent drop in its stock price.
